evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,587 questions · 5,761 findings · 495 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,011 · 17.5%GRADE not reported 1,797 · 31.2%Very low 1,100 · 19.1%Low 1,052 · 18.3%Moderate 649 · 11.3%High 152 · 2.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Target of exercise: hip vs knee exercises

Functional ability · patients with patellofemoral pain syndrome (symptoms > 1 month (1 study); symptoms > 6 months (1 study))

It is very uncertain whether target of exercise: hip changes functional ability (short‐term) Scale (0 to 100; higher scores mean… compared with knee exercises (very low certainty).

1 finding from 1 review

Target of exercise: hip vs knee exercises

Functional status, long‐term · patients with patellofemoral pain syndrome (symptoms > 1 month (1 study); symptoms > 6 months (1 study))

It is very uncertain whether target of exercise: hip changes functional ability (long‐term) WOMAC (0 to 96; inverted scores so… compared with knee exercises (very low certainty).

1 finding from 1 review

High‐intensity vs low‐intensity exercise programmes

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)

It is very uncertain whether high‐intensity changes usual pain (short‐term) VAS (0 to 10; higher scores mean worse pain) compared with low‐intensity exercise programmes (very low certainty).

2 findings from 1 review

Exercise therapy vs a control strategy (no treatment, placebo or waiting list controls)

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with patellofemoral pain syndrome (symptoms > 3 weeks (1 study); symptoms > 1 month (3 studies); symptoms > 2 months (2 studies);…

It is very uncertain whether exercise therapy changes usual pain (long‐term) VAS (0 to 10; higher scores mean worse pain) compared with a control strategy (no treatment, placebo or waiting list controls) (very low certainty).

1 finding from 1 review

High‐intensity vs low‐intensity exercise programmes

Functional ability · patients with patellofemoral pain syndrome (untreated PFPS of over 2 months in duration)

It is very uncertain whether high‐intensity changes functional ability (short‐term) FIQ modified (0 to 16; higher scores… compared with low‐intensity exercise programmes (very low certainty).

2 findings from 1 review

Exercise therapy vs a control strategy (no treatment, placebo or waiting list controls)

Functional ability · patients with patellofemoral pain syndrome (symptoms > 3 weeks (1 study); symptoms > 1 month (3 studies); symptoms > 2 months (2 studies);…

It is very uncertain whether exercise therapy changes functional ability (short‐term) Scale (0 to 100; higher scores mean… compared with a control strategy (no treatment, placebo or waiting list controls) (very low certainty).

2 findings from 1 review

Exercise therapy vs a control strategy (no treatment, placebo or waiting list controls)

Recovered · patients with patellofemoral pain syndrome (symptoms > 3 weeks (1 study); symptoms > 1 month (3 studies); symptoms > 2 months (2 studies);…

It is very uncertain whether exercise therapy changes recovery (long‐term) Number of patients who had recovered or number… compared with a control strategy (no treatment, placebo or waiting list controls) (very low certainty).

1 finding from 1 review

Ultrasound guidance vs anatomical landmarks

Other complications (thrombosis, embolism, haematomediastinum and hydromediastinum, haematothorax and hydrothorax, pneumothorax, subcutaneous emphysema, nerve injury) · patients with femoral vein cannulation for central vein catheterization

Ultrasound guidance showed no clear difference in other complications (thrombosis, embolism, haematomediastinum and… compared with anatomical landmarks (low certainty).

1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

1 finding from 1 review

Non-specific immunotherapy (recombinant interleukin-2 or BCG cell wall preparation) plus standard therapy vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Locoregional control · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

Quality of life · People with squamous cell carcinoma of the oral cavity or oropharynx
1 finding from 1 review

Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical…
    Studies not reported
    GRADE not reported